UK-based Allergy therapics group completes acquisition of Spanish company Alerpharma

, ,
Integral service around a transaction
BY : Diego GutiérrezJune Wed, 2016
The €3.8m acquisition of Spain's Allerpharma by UK-based Allergy Therapics was announced nine months ago and has recently been completed. The sale and purchase agreement includes an additional payment of up to €2M depending on the results obtained in 2016, so the sale could reach €5.8M. With the acquisition, Allergy Therapeutics absorbs Alerpharma and incorporates its employees into its current workforce.


About Alerpharma

Alerpharma Inmunal, based in Madrid, is a company dedicated to developing immunotherapy solutions for allergy and bacterial vaccines. Its main subsidiary is Inmunal, which was spun off from the biopharmaceutical company Zeltia and will continue to operate from its Madrid facilities.

Alerpharma bought Inmunal from the group Zeltia when two Zeltia group companies, Genómica and Pharma Gen, merged and Pharma Gen divested itself of businesses considered non-strategic, such as Inmunal.

About Allergy therapheutics

Allergy Therapeutics is a multinational biotechnology group specialising in the development of innovative therapies for the treatment and prevention of allergies. The group has more than 400 employees worldwide and specialises in the research, development and commercialisation of vaccines for immunotherapy and other allergy solutions.

The company is listed on the London Stock Exchange and is completing clinical trials of its lead product, Pollinex Quattro, for registration and launch in the United States, a market estimated to be worth more than $2 billion.

Reasons for purchase

Allergy Therapeutics had already been operating in Spain since 1999, which is its second largest market after Germany. With this acquisition, Allergy Therapheutics is able to improve control of its logistics in Spain, reduce costs and make the investment profitable by being able to carry out distribution from Madrid.

On the other hand, it will strengthen the consolidation of Allergy Therapeutics Ibérica in the Spanish market and thus reinforce its capacity to develop new vaccines, while allowing further progress in the research and development of new products.

In addition, Allergy Therapeutics will be able to incorporate new product lines already developed by Alerpharma, such as allergenic extracts and specific immunotherapy.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal with extensive experience in the biotech sector. Call us on + 34 944240141 or fill in the contact form.



The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?